Profile of antifungal susceptibility of species of Candida isolated from hemocultures in a University Hospital, Maracaibo, Venezuela;Perfil de sensibilidad antifúngica de especies de Candida aisladas de hemocultivos en un Hospital Universitario, Maracaibo, Venezuela

Revista Iberoamericana de Micologia

Volumn 23, Issue 2, 2006, Pages 97-100

  Arcaya, Noris Margarita ^a,d   Mesa, Luz Mila ^b   Pineda, Maritza Rebeca ^c   Beltrán Luengo, Haydee ^c   Calvo, Belinda Milagros ^b  

^a Universidad Nacional Experimental Francisco de Miranda   (Venezuela)

^b UNIVERSIDAD DEL ZULIA   (Venezuela)

^c Universitario de Maracaibo   (Venezuela)

^d Edif San Francisco Xavierus   (Venezuela)

Author keywords

Antifungal susceptibility; Candida; Hemocultures

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CEFTAZIDIME; FLUCONAZOLE; ITRACONAZOLE;

ARTICLE; BLOOD CULTURE; CANDIDA; CANDIDIASIS; FUNGUS ISOLATION; HOSPITALIZATION; HUMAN; IN VITRO STUDY; METHODOLOGY; SPECIES DIFFERENCE; UNIVERSITY HOSPITAL; VENEZUELA;

CANDIDA;

EID: 33746521120     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(06)70022-5     Document Type: Article

References (18)

1. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001; 45: 922-926.
2. Antibiotic Susceptibility. Method for determination of minimal inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Discussion document E. Dis. 7.1. Taufkirehen, European Society of Clinical Microbiology and Infections Diseases, 2002.
3. Carrillo AJ, Tur C, Estivill D, Montsant L, Carceller A, Hernández-Molina JM, Torres-Rodríguez JM. Resistencia in vitro al fluconazol e itraconazol en aislamientos clínicos de Candida spp y Crytococcus neoformans. Rev Iberoam Micol 1997; 14: 50-54.
4. Colombo AL, Nucci M, Salomao, Branchini ML, Ritchmann R, Derossi A, Wey BS. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect 1999; 34: 281-286.
5. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, Rodriguez-Tudela JL. Influence of glucosa supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. J Clin Microbiol 2001; 39: 525-532.
6. Cuenca-Estrella M, Rodera L, Garcia-Effron G, Rodriguez-Tudela JL. Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother 2002; 49: 981-987.
7. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, Pfaller MA, Rinaldi M, Rodriguez-Tudela JL, Verweij PE. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43: 3884-3889.
8. Godoy P, Tiraboshi IN, Severo LC, Bustamante B, Calvo B, De Almeida LP, Da Matta DA, Colombo AL. Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals. Mem Inst Oswaldo Cruz, 2003; 98: 401-405.
9. Laguna F, Rodriguez-Tudela JL, Martinez-Suarez JV, Polo R, Valencia E, Diaz-Guerra TM, Dronda F, Pulido F. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin Infect Dis 1997; 24: 124-130.
10. National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard M27-A, Wayne, PA, 1997.
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A2, Wayne, PA, 2002.
12. Pfaller MA, Barry AL. In vitro susceptibility of clinical yeast isolates to three antifungal agents determine by the microdilution method. Mycopathologia 1995; 130: 3-9.
13. Pfaller MA, Diekema DJ, Mecer SA, Boyken L, Mollis RJ, Jones RN, and the International Fungal Surveillance Participant Group. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003; 41: 78-83.
14. Pfaller MA, Diekema DJ, Jones RN, Mecer SA, Hollis RJ, and the SENTRY Participants Group. Trends in antifungal susceptibility of Candida spp. Isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002; 40: 852-856.
15. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Mollis RJ, Messer SA, and the SENTRY Participant group, International surveillance of bloodstream infections due to Candida species: frecuency of occurrence and in vitro susceptibility to fluconazol, ravuconazol, and voriconazol of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 2001; 39: 3254-3259.
16. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis J, Messer SA, for the SENTRY Participant Group, International surveillance of bloodstream infections due to Candida species: frecuency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY program. J Clin Microbiol 1998; 36: 1886-1889.
17. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rinaldi MG, Sheehan DJ, Warnock DW. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-658.
18. Rodriguez-Tudela JL, Cuenca-Estrella M, Diaz-Guerra TM, Mellado E. Standardization of antifungal susceptibility variables for a semiautomated methodology. J Clin Microbiol 2001; 39: 2513-2517.